Introduction: In recent years, cancer resistance lines are major obstacles in treatment of cancers. However, new emerging technologies such as crisper and recent generation of drugs have been emerged. Despite these significant advances, many cancerous cells are prompt to resist spontaneously. Here with the assistance of bioinformatics, we analysis MCF7 cell line, and ADR/MCF7 line which has resistance to endocrine therapies. The data demonstrate long term usage of Doxorobicn could lead to endocrine resistance, in spite its unrelated and divergent mechanism.
Methods: Eight SRA files from NCBI have been analyzed and heat maps have been drawn. The significant subset of differentiated expressed genes have been extracted by GEO2R and the network provided by string package.
Results: By analysis of this data, it has been shown that Doxorobicin activate the endocrine resistance pathway, despite the activation of apoptosis and necrosis pathway. This data demonstrated that this drug must be used with extra attention and persuasions.
Conclusion: Speller and grammar checker English
It can be concluded that as useful as Doxorobicin could be for cancer treatment, its usage on this specific cancer lines must be hindred. The administration of this drug could lead to a resistance cancer line and diseases in patients who take this substance as a solution to their problems.